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To the editor: We read with great interest the recent 
article by Rantakokko-Jalava et al. about false-negative 
Chlamydia trachomatis (CT) specimens in the nucleic 
acid amplification test (NAAT) Aptima Combo 2 assay 
(AC2; Hologic Inc.) [1]. These very important findings 
indicate that 6–10% of CT-positive cases in Finland 
might have been missed due to false-negative/equivo-
cal AC2 results. The AC2 false-negative/equivocal CT 
specimens were observed in several Finnish settings, 
particularly in south-western Finland, June 2018–April 
2019. Finnish experts, together with Hologic scientists, 
quickly determined that the specimens with equivocal/
negative CT results in AC2 (target: 23S rRNA) but posi-
tive in the Aptima Chlamydia trachomatis assay (ACT; 
target: 16S rRNA) were not linked to Hologic instru-
ments or reagents. Concurrently, Finnish scientists 
identified a C1515T mutation in the CT 23S rRNA gene in 
10 AC2 false-negative specimens [1]. Further investiga-
tion and response is required and will need collabora-
tive action.
Hologic has now provided strong evidence that the 
C1515T mutation is the root cause of the AC2 false-
negative/equivocal CT specimens and confirmed in 
analytical studies that a synthetic RNA transcript cor-
responding to the CT 23S rRNA with a C1515T mutation 
yields significantly suppressed CT detection probe-sig-
nal in AC2 similar to that observed with AC2 testing of 
clinical samples containing the mutated CT strain.
It is essential that a broader understanding is devel-
oped of the presence and proportion of specimens with 
mutated CT in Finland and internationally. Sufficient 
numbers of representative, geographically diverse 
false-negative AC2 specimens need to be examined 
in order to exclude the unlikely possibility of addi-
tional 23S rRNA mutations affecting detection. Using 
ACT for confirmation of AC2 screened specimens pro-
vides clinical utility in the short term but is not a fea-
sible long-term solution, because of the high cost and 
substantially increased work load and time for report-
ing results imposed by confirming a large number of 
AC2 equivocal/negative specimens by ACT testing. 
Additionally, the different performance characteristics 
of AC2 and ACT may further confound our understand-
ing of the presence, spread and possible evolution of 
the new mutant (or, although unlikely, mutants). This 
might even result in the use of only ACT in some set-
tings, which would create problems due to the wide-
spread use of AC2 as well as loss of information 
regarding the presence of mutated specimens, pres-
ence of Neisseria gonorrhoeae, and the advantage of 
reserving ACT for confirmation testing.
Instead, until a revised version of the AC2 test is avail-
able, a validated and quality-assured ‘mutant-specific’ 
research-use-only test is urgently needed to under-
stand the geographic distribution of the CT mutant and 
its prevalence in screening populations. To fulfil this 
need, Hologic is rapidly developing an Aptima-format 
research kit containing a 23S rRNA-mutant detec-
tion probe. Surveillance using a test that detects the 
CT mutant will provide further timely insight into the 
impact of this CT variant on the effectiveness of CT 
screening in Finland and additional European countries 
where elevated levels of AC2 false-negative/equivocal 
results might be observed. In addition, this mutant-
specific assay will generate evidence-based modifica-
tions to the current AC2 assay to ensure accuracy of 
test results and patient safety. The European Centre for 
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Disease Prevention and Control (ECDC) intends to facil-
itate such preferably centralised study or studies which 
will require close collaboration with Finland, additional 
European Union/European Economic Area countries, 
other international and national public health organi-
sations, and Hologic.
The key public health priorities include understanding 
the spread of the CT mutant and ensuring that patients 
with false-negative results are recalled and tested 
using alternative NAAT. To address the former, any 
unexplained changes in CT epidemiology and positiv-
ity rate need to be further investigated. In laboratories 
using AC2, retrospective and prospective review of the 
AC2 test results (proportions of positive, equivocal, 
negative test results, and associated relative light units 
(RLU) of test results) and investigations of any unex-
plained changes in the CT positivity rate should be per-
formed. In settings with suspected false-negative CT 
test results by AC2, to ensure patient safety, specimens 
with low CT RLU values (≥15–99), independent of the 
result interpretation in the Hologic instruments, need 
retesting with an appropriate NAAT targeting another 
genetic sequence (preferably ACT), and not by repeated 
AC2 testing. The look-back period for recalling patients 
with verified false-negative results will depend on the 
local proportion and epidemiology of the CT mutant; 
taking into account spontaneous clearance of CT infec-
tion, social consequences for the patients, potential 
risk of reinfection, and continuous analysis of positiv-
ity rates of retested patients.
Investigation of additional scientific issues will be 
important in due course, e.g. if it is only one mutated 
CT clone; the emergence (when, where and how), trans-
mission and evolution of the clone(s) in different popu-
lations in Finland and possibly other countries; if the 
clone(s) has(ve) any fitness advantage/disadvantage; 
if only one or both the CT 23S rRNA gene alleles are 
mutated in all specimens and how this affects the 
number or proportion of mutated 23S rRNA molecules 
detected in AC2; if the lack of AC2 detection of the 
clone(s) has increased risk of CT-associated compli-
cations/sequelae; associations between the clone(s) 
and symptomatic/asymptomatic infection, and spread 
in different subpopulations (patient sex, age, sex-
ual orientation, geographic distribution etc.). Whole 
genome sequencing from false-negative AC2 CT speci-
mens is in progress to address several of these issues. 
Furthermore, a mutant-specific real-time PCR is also 
under development.
Finally, it is likely that mutants of CT and other infec-
tious agents escaping detection in commercial and 
laboratory-developed diagnostic NAATs are more 
common than previously realised and are inevitable 
consequences of the microbial evolution combined 
with the high diagnostic selective pressure on the 
microorganisms. Several lessons on such diagnosti-
cally-selected evolution can be learnt from the identifi-
cation of the Swedish new variant of CT (nvCT) in 2006 
and its subsequent spread mainly in Sweden [2-5]. 
International and national surveillance programmes 
capturing diagnostic test escape mutants (as well as 
cross-reacting mutants of other pathogens) for CT and 
other pathogens should be considered, particularly for 
diagnostic NAATs with a single genetic target region.
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